Phase III, Double-Blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (Genentech CO41101)

Study Details

This study will evaluate the efficacy, safety, and pharmacokinetics of ipatasertib in combination

with atezolizumab and paclitaxel in locally advanced unresectable or metastatic triple-negative

breast cancer (TNBC) previously untreated in this setting. NCT number
NCT Not Available

Principal Investigators

  • Steve Lo, MD
Genentech, Inc.
Mary Miller, LPN at 203-358-8879


  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695
There is no panel matching the key "Cookie-Notification"